



Docket No. ORT-1237

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Zhang et al.

Serial No. : 09/603,338

Art Unit: 1653

Filed : June 26, 2000

Examiner: A.A. Mohamed

For : NOVEL INDOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR
ANTAGONISTS

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

May 23, 2002

(Date)

Hal B. Woodrow

Name of applicant, assignee, or Registered Representative

Hal B. Woodrow
(Signature)

May 23, 2002

(Date of Signature)

RECEIVED
JUN 11 2002
TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE

Pursuant to the requirements of 37 CFR 1.822 and/or 1.823 and further to the Formalities Letter mailed April 23, 2002, Applicant submits a corrected copy of the Sequence Listing in computer readable form, including a printed version of the Sequence Listing of the subject application. As required, a copy of the Formalities Letter is also attached.

Furthermore, a Verified Statement concerning the enclosed diskette is submitted herewith.

If any fees are due in connection with the filing of this response, authorization is hereby given to charge the amount of such fee to Deposit Account No. 10-0750/ORT-1238/HBW in the name of Johnson & Johnson.

Respectfully submitted,

Hal Woodrow

Hal B. Woodrow

Reg. No. 32,501

Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2976
DATE: May 23, 2002



Docket No. ORT-1237

1653/Box 59

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#8/A
9th
6/30/02

Applicants : Zhang et al.
Serial No. : 09/603,338
Filed : June 26, 2000
Title : NOVEL INDOLE PEPTIDOMIMETICS AS
THROMBIN RECEPTOR ANTAGONISTS
Art Unit : 1653
Examiner : A. A. Mohamed

RECEIVED

JUN 11 2002

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231 on

May 23, 2002
(Date of Deposit)

Hal B. Woodrow
(Name of applicant, assignee, or Registered Representative)

COPY OF PAPERS
ORIGINALLY FILED

Hal B. Woodrow
(Signature)

May 23, 2002
(Date of Signature)

Honorable Commissioner of Patents
Washington, D.C. 20231

AMENDMENT

Dear Sir:

In response to the Office Action of April 23, 2002, Notice to Comply with Sequence Rules, please amend the above-identified application as follows:

In the Specification:

Please replace the paragraph beginning on page 1, line 15, with the following rewritten paragraph:

Thrombin is an important serine protease in hemostasis and thrombosis. One of the key actions of thrombin is cellular modulation via receptor activation. A functional human thrombin receptor (PAR-1), cloned by Coughlin in 1991 (T.-K. Vu, Cell 1991, 64, 1057), was found to be a member of the G-protein coupled receptor (GPCR) superfamily. The receptor

A1